Did you mean amitifadine of en 100 of dov 21,947 of アミティファジン?
Displaying drugs 126 - 150 of 234 in total
ARM-210
Investigational
STM-217
Investigational
Cosfroviximab
Investigational
Reldesemtiv
Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).
Investigational
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
PD-217014
PD-217,014 has been used in trials studying the treatment of Pain and Irritable Bowel Syndrome.
Investigational
EP-217609
Investigational
IPH 2101
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
ASP-2138
ASP-2138 is a bispecific antibody directed against CLDN18.2 and T cell receptor complex CD3
Investigational
Avasopasem
Investigational
Dotamtate Pb-212
Investigational
Denenicokin
Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).
Investigational
Matched Synonyms: … IL-21 recombinant ... Recombinant human IL-21 ... L-METHIONYL(HUMAN INTERLEUKIN-21) …
Matched Description: … -21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma). ... Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL …
Matched Description: … -21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma). ... Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL …
EP-2104R
EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.
Investigational
TK216
Investigational
PW2101
PW2101 is a beta blocker intended for the treatment of hypertension and angina. The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals. The development of PW2101 has since been discontinued.
Investigational
CNV-2197944
CNV-2197944 is under investigation in clinical trial NCT01893125 (Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy).
Investigational
PAS219
Experimental
Naphthalene-2,6-disulfonic acid
Experimental
RLYB212
RLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Investigational
Displaying drugs 126 - 150 of 234 in total